Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls

Gynecological Endocrinology

Volumn 26, Issue 3, 2010, Pages 201-207

  Stojanovic, Nemanja ^a   Lewandowski, Krzysztof ^b   Salata, Ireneusz ^b   Bienkiewicz, Malgorzata ^c   Tuck, Susan ^d   Prelevic, Gordana ^d   Press, Martin ^d  

^a QUEEN S HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Insulin resistance; MMPs; Pregnancy; TIMPs

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GESTATIONAL AGE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THIRD TRIMESTER PREGNANCY;

EID: 77249157286     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590902972026     Document Type: Article

References (29)

1. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 2002;12:655-662.
2. Galis ZS, Sukhova GK, Lark MV, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
3. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998;18: 1163-1172.
4. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Shultz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-1549.
5. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 2000;8:31-39.
6. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
7. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
8. Bai SX, Wang YL, Qin L, Xiao ZJ, Herva R, Piao YS. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy. Reproduction 2005;129:103-113.
9. Parry S, Strauss JF. Premature rupture of the fetal membranes. N Engl J Med 1998;338:663-670.
10. Paradisi G, Biaggi A, Ferrazzani S, De Carolis S, Caruso A. Abnormal glucose metabolism during pregnancy - association with endothelial dysfunction. Diabetes Care 2002;25:560-564.
11. Anastasiou E, Lekakis JP, Alevizaki M, Papamichael CM, Megas J, Souvatzoglou A, Stamatelopoulos SF. Impaired endothelium-dependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998;21:2111-2115.
12. CA Crowther, JB Hiller, JR Moss, AJ McPhee, WS Jeffries JS. Robinson for the Australian carbohydrate intolerance study in pregnant women (ACHOIS) trial group: effect of treatment of gestational diabetes mellitus on pregnancy outcomes. NEMJ 2005;352:2477-2486.
13. O'Sullivan JB. Diabetes mellitus after GDM. Diabetes 1991; 40 (suppl 2):131-135.
14. Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, Petrina M, Nicotra GS, Indelicato M, Navolanic PM, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1-6.
15. Matthews DR, Hosker JP, Rudensky AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
16. Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;9: 1462-1470.
17. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, Vatish M, Lewinski A, Prelevic GM, Randeva HS. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033-1037.
18. O'Sullivan JB, Mahan CM, Charles D, Dandrow RV. Screening criteria for high risk gestatonal diabetic patients. Am J Obstet Gynecol 1973;116:895-900.
19. WHO. WHO consultation: definition, diagnosis, and classification of diabetes mellitus and its complications report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO/NCD/NCS/99.2, World Health Org; 1999.
20. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684.
21. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002;51:3063-3068.
22. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006;99:140-148.
23. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997;40:1449-1454.
24. Bevier WC, Fischer R, Jovanovic L. Treatment of women with an abnormal glucose challenge test (but a normal oral glucose tolerance test) decreases the prevalence of macrosomia Am J Perinatol 1999;16:269-275.
25. Mello G, Parretti E, Mecacci F, Lucchetti R, Lagazio C, Pratesi M, Scarselli G. Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test. Eur J Endocrinol 1997;137:27-33.
26. Volpe L, Cuccuru I, Lencioni C, Napoli V, Ghio A, Fotino C, Bertolotto A, Penno G, Benzi L, Del Prato S, et al. Early subclinical atherosclerosis in women with previous gestational diabetes mellitus. Diabetes Care 2008;31:e32. http://care. diabetesjournals.org.
27. Goldman S, Weiss A, Eyali V, Shalev E. Differential activity of the gelatinases (matrix metalloproteinases 2 and 9) in the fetal membranes and decidua, associated with labour. Mol Hum Reprod 2003;9:367-373.
28. Pustovrh MC, Jawerbaum A, Capobianco E, White V, López- Costa JJ, González E. Increased matrix metalloproteinases 2 and 9 in placenta of diabetic rats at midgestation. Placenta 2005;26:339-348.
29. Pustovrh C, Jawerbaum A, Sinner D, Pesaresi M, Baier M, Micone P, Gimeno M, Gonzalez ET. Membrane-type matrix metalloproteinase-9 activity in placental tissue from patients with pre-existing and gestationaldiabetes mellitus. Reprod Fertil Dev 2000;12:269-275.